# US 2025/0375528 A1 · Conjugate of cell-penetrating peptide and melphalan, and preparation containing conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375528 A1
- Document ID: US20250375528A1
- Status: Published application
- Kind: A1
- Application number: 18/580,492
- Filed: 2022-07-21
- Published: 2025-12-11
- Earliest claimed: 2021-07-21
- Applicants: Alephoson Biopharmaceuticals Limited
- Inventors: Gang WEI; Kuan JIANG; Benjamin Tak Kwong LEE; Yanfeng WANG
- Web page: https://patentgrep.com/patent/US20250375528A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a conjugate of cell-penetrating peptide and melphalan and a formulation comprising the same. Specifically, the present invention relates to a conjugate formed by covalently linking cell-penetrating peptide derivative to melphalan, a formulation comprising the conjugate, a method for treating diseases with the conjugate, and the application of the formulation in treating diseases.

## Claims

### Claim 1

A compound of formula (I), (II) or (III), or a pharmaceutically acceptable salt thereof, which represents a covalent conjugate of cell-penetrating peptide derivative and melphalan,
wherein, X1, X2 and X3 represent hydrophobic amino acid, each of which is independently selected from alanine (A), valine (V), leucine (L), isoleucine (I), proline (P), phenylalanine (F), tryptophan (W), methionine (M) and non-naturally occurring amino acids α-aminobutyric acid, α-aminopentanoic acid, α-aminohexanoic acid and α-aminoheptanoic acid;
Z1 and Z2 represent naturally or non-naturally occurring amino acids, which is independently selected from 1, 2, 3, 4 or 5 of glycine (G), alanine (A), lysine (K), arginine (R), serine (S), histidine (H), aspartic acid (D), glutamic acid (E), threonine (T), proline (P), cysteine (C), tyrosine (Y), valine (V), methionine (M), isoleucine (I), leucine (L), phenylalanine (F), tryptophan (W), Glutamine (Q), Asparagin (N), and non-naturally occurring hydroxyproline, α-aminobutyric acid, α-aminopentanoic acid, α-aminohexanoic acid and α-aminoheptanoic acid, and the numbers of Z1 and Z2 are independent of each other;
n is an integer ranging from 0 to 10, preferably from 0 to 5, for example 0, 1, 2, 3, 4 or 5;
Mel is the melphalan moiety, and
linker represents a covalent bond or a linking group formed between melphalan and the adjacent amino acid, such as amide bond, ester bond, ether bond, disulfide bond, hydrazone, urea, oxime, guanidine, amidine, acetal, imine, alkylene or other linking forms; for example, linker can be selected from the following forms: —O—, —S—, —S—S—, —CH═N—O—, —C1-6 alkylene-, —NH—, —N(R1)—, —CO—NH—, —CO—N(R1)—, —C1-6 alkylene-(CO—NH)—, —C1-6 alkylene-(CO—N(R1))—, —C1-6 alkylene-N(R1)—, —NH—CO—, —N(R1)—CO—, —C1-6 alkylene-NH—CO—, —C1-6 alkylene-N(R1)—CO—, —NH—CO—NH—, —N(R1)—CO—NH, —NH—CO—N(R1)—, —N(R1)—CO—N(R1), —C(═O)O—, —C1-6 alkylene-C(═O)O—, —C(═O)O—C1-6 alkylene-, —S(—O)NH—, —S(═O)N(R1)—, —NH—S(═O)—, —N(R1)S(═O)—, —C1-6 alkylene-S(═O)NH—, —C1-6 alkylene-S(═O)N(R1)—, —C1-6 alkylene-NH—S(═O)—, —C1-6 alkylene-N(R1)S(═O)—, —S(═O)2—NH—, —S(═O)2—N(R1)—, —NH—S(═O)2—, —N(R1)S(═O)2—, —C1-6 alkylene-S(═O)2—NH—, —C1-6 alkylene-S(═O)2—N(R1)—, —C1-6 alkylene-NH—S(═O)2—, —C1-6 alkylene-N(R1)S(═O)2—, or C1-6 alkylene substituted with one or more R1; wherein R1 is selected from C1-6 alkyl, C3-8 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl or 3- to 12-membered heterocycloalkyl, each of which is optionally substituted with one or more groups independently selected from halogen, amino, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, halogen-substituted C1-6 alkyl, halogen-substituted C1-6 alkoxy, halogen-substituted C2-6 alkenyl or halogen-substituted C2-6 alkynyl.

### Claim 2 (depends on 1)

The compound according to claim 1, which is a compound of formula (IV), wherein an amide bond connection is directly formed by the amino group of melphalan and the carboxyl group terminal of the cell-penetrating peptide derivative:
wherein the “cell-penetrating peptide” moiety is as defined for the compound of formula (I), (II) or (III) in claim 1.

### Claim 3 (depends on 2)

The compound according to claim 2, which is a compound of formula (V), or a pharmaceutically acceptable salt thereof,
wherein, Mel is the melphalan moiety shown in formula (IV), and the free amino group of Mel forms an amide bond —(CO—NH)— with the carboxyl group of the C-terminal Lys of the cell-penetrating peptide,
X1, X2 and X3 represent hydrophobic amino acids, each of which is independently selected from alanine (A), valine (V), leucine (L), isoleucine (I), proline (P), phenylalanine (F), tryptophan (W), methionine (M) and non-naturally occurring amino acids α-aminobutyric acid, α-aminopentanoic acid, α-aminohexanoic acid and α-aminoheptanoic acid.

### Claim 4 (depends on 3)

The compound according to claim 3, wherein any one of X1, X2 and X3 of the compound of formula (V) is tryptophan.

### Claim 5 (depends on 3)

The compound according to claim 3, wherein any two of X1, X2 and X3 of the compound of formula (V) are tryptophan.

### Claim 6 (depends on 3)

The compound according to claim 3, wherein all of X1, X2 and X3 of the compound of formula (V) are tryptophan.

### Claim 7 (depends on 3)

The compound according to claim 3, wherein the compound of formula (V) is selected from the following compounds or a pharmaceutically acceptable salt thereof:
Number
Sequence
2WP-Mel
RWIKIWFQNRRMKWKK-(CO-NH)-Mel
8WP-Mel
RQIKIWFWNRRMKWKK-(CO-NH)-Mel
9WP-Mel
RQIKIWFQWRRMKWKK-(CO-NH)-Mel
28WP-Mel
RWIKIWFWNRRMKWKK-(CO-NH)-Mel
29WP-Mel
RWIKIWFQWRRMKWKK-(CO-NH)-Mel
89WP-Mel
RQIKIWFWWRRMKWKK-(CO-NH)-Mel
289WP-Mel
RWIKIWFWWRRMKWKK-(CO-NH)-Mel

### Claim 8 (depends on 3)

The compound according to claim 3, wherein the compound of formula (II) is selected from the following compounds or a pharmaceutically acceptable salt thereof:
Number
sequence
89WP-Mel
RQIKIWFWWRRMKWKK-(CO-NH)-Mel
289WP-Mel
RWIKIWFWWRRMKWKK-(CO-NH)-Mel

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients or carriers.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, which is in the form of a liquid pharmaceutical composition.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, which is in the form of injection solution or eye drops.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A method for preventing or treating eye diseases, comprising administering a compound of formula (II) or a pharmaceutically acceptable salt thereof according to claim 1 to an individual in need thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the eye diseases are selected from: tumors of eyelids, conjunctiva, various layer tissues of eyeball (cornea, sclera, uvea and retina) and appendages of the eyes (lacrimal apparatus, orbital and periorbital structures), including malignant basal cell carcinoma, meibomian gland carcinoma, squamous epithelial carcinoma, melanoma, retinoblastoma, choroidal melanoma, rhabdomyosarcoma, lacrimal gland adenocarcinoma, benign choroidal hemangioma, optic nerve glioma, neurofibroma, keratosis, nevus, dermoid tumor, cavernous hemangioma, dermoid cyst, lacrimal gland mixed tumor, and intraocular metastatic carcinoma, particularly retinoblastoma and choroidal melanoma, and also uveitis.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the eye disease is retinoblastoma.
